IL257940B - Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof - Google Patents

Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof

Info

Publication number
IL257940B
IL257940B IL257940A IL25794018A IL257940B IL 257940 B IL257940 B IL 257940B IL 257940 A IL257940 A IL 257940A IL 25794018 A IL25794018 A IL 25794018A IL 257940 B IL257940 B IL 257940B
Authority
IL
Israel
Prior art keywords
ccl22
seq
cells
peptide
sequence identity
Prior art date
Application number
IL257940A
Other languages
English (en)
Hebrew (he)
Other versions
IL257940A (en
Original Assignee
Herlev Hospital
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herlev Hospital, Io Biotech Aps filed Critical Herlev Hospital
Publication of IL257940A publication Critical patent/IL257940A/en
Publication of IL257940B publication Critical patent/IL257940B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001142—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4236—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL257940A 2015-09-16 2016-09-16 Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof IL257940B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201570591 2015-09-16
PCT/DK2016/050301 WO2017045691A1 (en) 2015-09-16 2016-09-16 Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof

Publications (2)

Publication Number Publication Date
IL257940A IL257940A (en) 2018-05-31
IL257940B true IL257940B (en) 2022-08-01

Family

ID=57123753

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257940A IL257940B (en) 2015-09-16 2016-09-16 Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof

Country Status (8)

Country Link
US (3) US11298413B2 (OSRAM)
EP (1) EP3349785A1 (OSRAM)
JP (1) JP6924747B2 (OSRAM)
CN (2) CN116333088A (OSRAM)
AU (1) AU2016322506B2 (OSRAM)
HK (1) HK1257448A1 (OSRAM)
IL (1) IL257940B (OSRAM)
WO (1) WO2017045691A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016322506B2 (en) * 2015-09-16 2023-02-09 Io Biotech Aps Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
JP2021515797A (ja) * 2018-03-15 2021-06-24 アトッサ・セラピューティクス・インコーポレイテッド 免疫反応誘導のインサイツ方法
FR3084463B1 (fr) * 2018-07-30 2023-04-21 Francais Du Sang Ets Procede d'analyse des plaquettes d'un echantillon sanguin
MX2023001182A (es) * 2020-07-30 2023-02-22 Ct Inmunologia Molecular Uso de agentes depletantes del factor de crecimiento epidermico en el tratamiento de la enfermedad pulmonar obstructiva cronica.
WO2024168311A2 (en) * 2023-02-09 2024-08-15 The Brigham And Women’S Hospital, Inc. Autonomous gene circuits for therapy release

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
US7018627B1 (en) * 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5932703A (en) * 1995-06-07 1999-08-03 Icos Corporation Macrophage derived chemokine and chemokine analogs
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US8563476B2 (en) * 2002-11-15 2013-10-22 Morehouse School Of Medicine Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders
EP1613308A4 (en) * 2003-03-27 2008-02-20 Lankenau Inst Medical Res CANCER TREATMENT METHODS
US20100113342A1 (en) * 2006-06-20 2010-05-06 Yount Nannette I Antimicrobial kinocidin compositions and methods of use
CN102088994B (zh) 2008-04-17 2014-06-25 海莱乌医院 基于吲哚胺2，3-双加氧酶的免疫疗法
WO2011006029A1 (en) * 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
WO2011139738A2 (en) 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
JP6259763B2 (ja) 2011-10-17 2018-01-10 ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ Ｐｄ−ｌ１に基づく免疫療法
EP2800762B1 (en) * 2012-01-03 2018-01-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
US20150359869A1 (en) 2012-08-15 2015-12-17 Cyvax, Inc. Methods and compositions for preventing a condition
JP6401702B2 (ja) * 2012-09-07 2018-10-10 ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ 炎症性肝疾患の診断のための方法および組成物
WO2014170389A1 (en) 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US10130454B2 (en) 2014-08-01 2018-11-20 Iowa State University Research Foundation, Inc. Vaccine delivery devices
AU2016322506B2 (en) 2015-09-16 2023-02-09 Io Biotech Aps Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018627B1 (en) * 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor

Also Published As

Publication number Publication date
AU2016322506A1 (en) 2018-04-12
CN116333088A (zh) 2023-06-27
HK1257448A1 (zh) 2019-10-18
WO2017045691A9 (en) 2018-06-28
US12496333B2 (en) 2025-12-16
JP6924747B2 (ja) 2021-08-25
US20220339273A1 (en) 2022-10-27
NZ740930A (en) 2024-09-27
CN108472345A (zh) 2018-08-31
IL257940A (en) 2018-05-31
WO2017045691A1 (en) 2017-03-23
CA2998789A1 (en) 2017-03-23
US11298413B2 (en) 2022-04-12
CN108472345B (zh) 2023-05-23
US20230241191A9 (en) 2023-08-03
AU2016322506A9 (en) 2018-12-06
AU2016322506B2 (en) 2023-02-09
EP3349785A1 (en) 2018-07-25
US20220280624A1 (en) 2022-09-08
JP2018528960A (ja) 2018-10-04
US20190008939A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
US12233103B2 (en) Indoleamine 2,3-dioxygenase based immunotherapy
CA2850245C (en) Pd-l1 based immunotherapy
US12496333B2 (en) Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
US11878053B2 (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
CA2998789C (en) Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
HK1247114A1 (en) Indoleamine 2, 3-dioxygenase based immunotherapy